EUVIMEDObjevte EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules

Peter J Attia, Sree Chinta, Joseph Celidonio, John Sebastian De Armas, Evelyne Kalyoussef, Dylan F Roden iD

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70400 ↗

At a glance

Multizentrische Studie in Otolaryngology–Head and Neck Surgery, 2026. Written by Peter J Attia and 5 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Major MEDLINE topics: Thyroid Nodule, Hispanic or Latino, Black or African American, Thyroid Neoplasms. 60 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

About 20% of thyroid nodules detected on ultrasound are cytologically indeterminate (Bethesda categories III and IV), but the rate of malignancy of these nodules is less than 36%. The ability of Afirma Genomic Sequencing Classifier (GSC) to further risk‐stratify indeterminate thyroid nodules among Black and Hispanic patients is understudied. Study Design Retrospective Chart Review.

Setting

Two Academic Medical Centers.

Methods

Black and Hispanic patients who underwent Afirma GSC from 2017 to 2024 were included. Demographics, clinical history, GSC results, and surgical pathology reports were captured. Univariate analysis was conducted to elucidate demographic and clinical characteristics of this population, and confusion matrices evaluated GSC test performance.

Results

160 patients were included in this cohort with a median age at diagnosis of 51 years, 142 (88.8%) females, 86 (53.8%) Black, and 74 (46.2%) Hispanic. Median nodule size was 2.4 cm, 167 were Bethesda III, and 17 were Bethesda IV. Of the 184 Bethesda III and IV thyroid nodules tested with GSC, 131 (71.2%) were reported as benign. In total, 59 nodules (29.4%) were resected, with 19 malignancies. The observed values of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 89.5%, 78.2%, 32.1%, and 98.5%. For all specimens with oncocytic cytology (n = 45), the sensitivity, specificity, PPV, and NPV were 83.3%, 69.2%, 29.4%, and 96.4%, respectively.

Conclusions

This represents the largest study of Afirma GSC involving Black and Hispanic patients. In this cohort, the diagnostic performance of the Afirma GSC was comparable to that observed in the original validation study.

Subjects

MeSH terms (MEDLINE)

Thyroid NoduleHispanic or LatinoBlack or African AmericanThyroid NeoplasmsHumansFemaleRetrospective StudiesMiddle AgedMaleGenomicsAdult

Author keywords

indeterminate thyroid nodulesnext generation sequencingracial disparitiesthyroid cancerthyroidectomy

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

ORCID profiles: Dylan F Roden

Cite

APA

Attia, P. J., Chinta, S., Celidonio, J., Armas, J. S., Kalyoussef, E., & Roden, D. F. (2026). The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70400

Vancouver

Attia PJ, Chinta S, Celidonio J, Armas JS, Kalyoussef E, Roden DF. The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70400

BibTeX
@article{Attia2026,
  author = {Attia, Peter J and Chinta, Sree and Celidonio, Joseph and Armas, John Sebastian De and Kalyoussef, Evelyne and Roden, Dylan F},
  title = {The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70400}
}
Start for free →